Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients

Feletar, Marie

doi:10.1136/ard.2003.006775

Cited by 63 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidences of adverse events, serious adverse events, and infections were similar between treatment groups. Overall, the safety of adalimumab was similar to that reported in studies of adalimumab in RA (25)(26)(27) and to that reported in previous studies of other therapies in PsA (11,20,50,51).…”

Section: Discussionsupporting

confidence: 86%

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

Mease

Gladman

Ritchlin

et al. 2005

Arthritis & Rheumatism

837

629

View full text Add to dashboard Cite

Objective. Adalimumab, a fully human, antitumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA).Methods. Patients with moderately to severely active PsA and a history of inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive 40 mg adalimumab or placebo subcutaneously every other week for 24 weeks. Study visits were at baseline, weeks 2 and 4, and every 4 weeks thereafter. The primary efficacy end points were the American College of Rheumatology 20% improvement (ACR20) response at week 12 and the change in the modified total Sharp score of structural damage at week 24. Secondary end points were measures of joint disease, disability, and quality of life in all patients, as well as the severity of skin disease in those patients with psoriasis involving at least 3% of body surface area.Results. At week 12, 58% of the adalimumabtreated patients (87 of 151) achieved an ACR20 response, compared with 14% of the placebo-treated patients (23 of 162) (P < 0.001). At week 24, similar ACR20 response rates were maintained and the mean change in the modified total Sharp score was ؊0.2 in patients receiving adalimumab and 1.0 in those receiving placebo (P < 0.001). Among the 69 adalimumabtreated patients evaluated with the Psoriasis Area and Severity Index (PASI), 59% achieved a 75% PASI improvement response at 24 weeks, compared with 1% of the 69 placebo-treated patients evaluated (P < 0.001). Disability and quality of life measures were also significantly improved with adalimumab treatment compared with placebo. Adalimumab was generally safe and welltolerated.Conclusion. Adalimumab significantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life in patients with moderately to severely active PsA.Psoriatic arthritis (PsA) is a chronic, inflammatory arthritis occurring in individuals with psoriasis. Psoriasis occurs in 2-3% of the US population (1). The reported range of prevalence of PsA in patients with psoriasis is 6-39%, depending on the population studied

show abstract

Section: Discussionsupporting

confidence: 86%

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

Mease

Gladman

Ritchlin

et al. 2005

Arthritis & Rheumatism

837

629

View full text Add to dashboard Cite

show abstract

“…Successively, Feletar et al [20] find a quite high incidence (3 patients on 16) of liver side effects during a study for the evaluation of infliximab efficacy in refractory psoriatic arthritis; however two of three patients were also taking methotrexate, and one of them had significant alcohol intake. The other one had only a moderate transaminasitis, and infliximab was discontinued for the poor clinical response of the psoriatic disease.…”

Section: Commentarymentioning

confidence: 99%

Infliximab-related hepatitis: discussion of a case and review of the literature

et al. 2010

View full text Add to dashboard Cite

Despite its rarity, infliximab-related hepatitis constitutes a cutting edge and challenging problem. In December 2004, a drug warning was issued by the Food and Drug Administration to alert healthcare professionals to the risk of hepatotoxicity in course of infliximab therapy. Subsequently, several reports of probable infliximab hepatitis have been published and interest is growing in trying to elucidate the impact of these events on clinical practice. After discussing our case report, the main characteristics of infliximab-mediated liver injury are analyzed, coupled with a review of the medical literature. Infliximab seems to provoke both immunomediated and a direct liver injury, but how this latter happens remains unclear. Moreover, infliximab immunomediated liver dysfunction resembles that of autoimmune hepatitis type I, with elevation of antinuclear, anti-smooth muscle, anti-double-strand DNA antibodies, and a clear preference for female sex. Finally, a flow chart is proposed with the purpose to help clinicians in the management of patients who develop signs of liver dysfunction during treatment with infliximab.

show abstract

“…3 Thrombocytopenia has occasionally been reported as an adverse reaction in efalizumab therapy, but has only sporadically been reported during anti-TNF-a therapies. [4][5][6][7][8][9][10][11][12][13] The frequency of this drug-related adverse event with anti-TNF-a treatment has not yet been investigated in a cohort of patients with psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Thrombocytopenia associated with the use of anti–tumor necrosis factor–α agents for psoriasis

Brunasso

Massone

2009

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients

Cited by 63 publications

References 29 publications

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

Infliximab-related hepatitis: discussion of a case and review of the literature

Thrombocytopenia associated with the use of anti–tumor necrosis factor–α agents for psoriasis

Contact Info

Product

Resources

About